Seres Therapeutics (MCRB) Non-Current Debt (2014 - 2024)
Seres Therapeutics (MCRB) posted Non-Current Debt of $102.5 million for Q2 2024, little changed sequentially from $102.0 million in Q1 2024, and up 1.74% YoY from $100.7 million in Q3 2023.
Seres Therapeutics (MCRB) Non-Current Debt (2014 - 2024) Analysis & Trends
Seres Therapeutics has reported Non-Current Debt for 11 years, with the latest figure at $102.5 million in Q2 2024.
- Quarterly Non-Current Debt rose 1.74% year-over-year to $102.5 million in Q2 2024, while the trailing twelve-month figure through Jun 2024 was $102.5 million (up 1.74% YoY) and the FY2023 annual result came in at $101.5 million, up 100.72% from the prior year.
- Non-Current Debt steadied at $102.5 million in Q2 2024 per MCRB's latest filing, from $102.0 million in the prior quarter.
- Over five years, Non-Current Debt peaked at $102.5 million in Q2 2024 and troughed at $16.1 million in Q3 2021.
- A 5-year average of $52.4 million and a median of $50.5 million in 2022 frame the typical range for Non-Current Debt.
- The sharpest annual moves came in 2021 and 2022: Non-Current Debt sank 35.47% in 2021, then surged 215.55% in 2022.
- Over 5 years, Non-Current Debt stood at $24.6 million in 2020, then increased by 0.02% to $24.6 million in 2021, then soared by 105.3% to $50.6 million in 2022, then soared by 100.72% to $101.5 million in 2023, then gained by 0.94% to $102.5 million in 2024.
- According to Business Quant data, Non-Current Debt over the past three periods registered $102.5 million, $102.0 million, and $101.5 million for Q2 2024, Q1 2024, and Q4 2023 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.04 Bn | 130.19 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.58 Bn | 77.59 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.34 Bn | 1.37 Bn | - |
| 4 | Moderna | 56.52 Bn | 51.38 Bn | 52.00 Mn | 591.00 Mn |
| 5 | BeOne Medicines | 42.04 Bn | 36.94 Bn | 1.53 Bn | 882.16 Mn |
| 6 | Alnylam Pharmaceuticals | 30.67 Bn | 27.36 Bn | 992.69 Mn | - |
| 7 | Insmed | 27.27 Bn | 26.11 Bn | 358.27 Mn | 546.77 Mn |
| 8 | BioNTech SE | 27.14 Bn | 8.75 Bn | 668.28 Mn | 360.97 Mn |
| 9 | Royalty Pharma | 27.12 Bn | 26.28 Bn | - | 8.96 Bn |
| 10 | Seres Therapeutics | 43.87 Mn | 43.87 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2024 | 102.49 Mn |
| Mar 31, 2024 | 102.01 Mn |
| Dec 31, 2023 | 101.54 Mn |
| Sep 30, 2023 | 101.14 Mn |
| Jun 30, 2023 | 100.74 Mn |
| Mar 31, 2023 | 51.23 Mn |
| Dec 31, 2022 | 50.59 Mn |
| Sep 30, 2022 | 50.86 Mn |
| Jun 30, 2022 | 50.63 Mn |
| Mar 31, 2022 | 50.44 Mn |
| Dec 31, 2021 | 24.64 Mn |
| Sep 30, 2021 | 16.12 Mn |
| Jun 30, 2021 | 19.04 Mn |
| Mar 31, 2021 | 21.87 Mn |
| Dec 31, 2020 | 24.64 Mn |
| Sep 30, 2020 | 24.98 Mn |
| Jun 30, 2020 | 24.86 Mn |
| Mar 31, 2020 | 24.75 Mn |
| Dec 31, 2019 | 24.65 Mn |
| Dec 31, 2018 | 6.78 Mn |